Anethole blocks both early and late cellular responses transduced by tumor necrosis factor: effect on NF-kappaB,...

Area of Science:

• Molecular Biology
• Cellular Biology
• Pharmacology

Background:

• Anethole, a natural compound, is known to inhibit inflammation and carcinogenesis.
• Tumor necrosis factor (TNF)-mediated signaling is implicated in both inflammation and carcinogenesis.
• The precise mechanisms by which anethole exerts its effects are not fully understood.

Purpose of the Study:

• To investigate the molecular mechanisms underlying anethole's anti-inflammatory and anti-carcinogenic effects.
• To determine if anethole modulates TNF-induced signaling pathways.
• To explore anethole's impact on key cellular responses to TNF.

Main Methods:

• Electrophoretic mobility shift assay (EMSA) to monitor NF-kappaB activation.
• Western blotting to assess IkappaBalpha phosphorylation and degradation.
• Reporter gene assays to quantify NF-kappaB activity.
• Caspase activation assays and cell viability measurements to assess apoptosis.
• Measurement of lipid peroxidation and reactive oxygen species (ROI) generation.

Main Results:

• Anethole potently inhibited TNF-induced NF-kappaB activation, a crucial early response.
• Anethole suppressed NF-kappaB activation induced by TRAF2 and NIK, suggesting action on IkappaBalpha kinase.
• Anethole blocked TNF-induced activation of AP-1, c-jun N-terminal kinase, and MAPK-kinase.
• Anethole abrogated TNF-induced apoptosis and reduced lipid peroxidation and ROI generation.
• Anethole analogues, eugenol and isoeugenol, also inhibited TNF signaling.

Conclusions:

• Anethole effectively inhibits multiple TNF-induced cellular responses, including NF-kappaB and AP-1 activation, apoptosis, and oxidative stress.
• These findings provide a molecular basis for anethole's observed anti-inflammatory and anti-carcinogenic properties.
• Anethole represents a promising natural compound for therapeutic strategies targeting inflammatory and carcinogenic processes.